The ability to customize the array was important to cover common and rare variation across populations genome-wide, with enhanced coverage in genes and regions related to addiction. Manufacturing reproducibility was also critical for translational and clinical use-cases that may be developed based on the array. Given these objectives, Affymetrix Axiom was selected as a platform for the array.
